MedPath

Multidisciplinary Association For Psychedelic Studies, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (100.0%)

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

Phase 2
Completed
Conditions
Posttraumatic Stress Disorder
Interventions
First Posted Date
2016-05-03
Last Posted Date
2023-07-12
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Target Recruit Count
80
Registration Number
NCT02759185
Locations
🇺🇸

Scottsdale Research Institute, Phoenix, Arizona, United States

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Phase 2
Withdrawn
Conditions
Stage IV Melanoma
Anxiety
Interventions
First Posted Date
2009-09-18
Last Posted Date
2023-12-26
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Registration Number
NCT00979693
Locations
🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety

Phase 2
Completed
Conditions
Anxiety
Interventions
First Posted Date
2009-06-15
Last Posted Date
2023-07-12
Lead Sponsor
Multidisciplinary Association for Psychedelic Studies
Target Recruit Count
12
Registration Number
NCT00920387
Locations
🇨🇭

Private Practices of Peter Gasser MD, Solothurn, Switzerland

News

FDA Approves Cannabis Study for PTSD in Veterans, Potentially Boosting Cannabis Stocks

The FDA has approved a study examining cannabis's therapeutic effects on 320 veterans with moderate to severe PTSD, a condition affecting roughly 7% of U.S. veterans.

FDA Approves Landmark Cannabis Study for PTSD Treatment in Veterans

The FDA has approved a study examining cannabis's therapeutic potential for treating post-traumatic stress disorder (PTSD) in 320 veterans.

FDA Approves Phase 2 Clinical Trial of Smoked Marijuana for PTSD in Veterans

The FDA has approved a Phase 2 clinical trial to evaluate smoked marijuana for treating PTSD in veterans, funded by Michigan cannabis sales tax revenue.

FDA Clears Phase 2 Trial of Smoked Cannabis for PTSD in Veterans

The FDA has cleared a Phase 2 trial to evaluate smoked cannabis in 320 veterans with moderate-to-severe PTSD who have prior cannabis use.

© Copyright 2025. All Rights Reserved by MedPath